GlassScriptPhysician profile
Timothy R Hines
NPI 1063446359
$1,840.91
in general payments reported to CMS, 2019-2025
17 companies · $546 in 2025
The $546 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $86.31 · 2021: $121 · 2022: $48.75 · 2023: $429 · 2024: $402 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,312 · Education: $64.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,312.38 |
| Education | $64.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $389.78 | 2022-2025 | |
| Novo Nordisk INC | $320.64 | 2024-2025 | Ozempic |
| Amgen INC. | $205.99 | 2020-2025 | Tavneos, Aranesp, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $187.02 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $155.22 | 2021-2025 | Lokelma, Farxiga |
| Aurinia Pharma U.S., INC. | $77.20 | 2021-2024 | Lupkynis |
| Glaxosmithkline, LLC. | $75.89 | 2023 | Benlysta, Jesduvroq |
| Vifor Pharma, INC. | $69.01 | 2023-2024 | Veltassa |
| Calliditas Therapeutics US INC. | $65.71 | 2024-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $59.41 | 2019-2023 | Korsuva, Velphoro |
| Horizon Therapeutics Plc | $50.34 | 2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $47.14 | 2023-2025 | Acthar, Terlivaz |
| Daiichi Sankyo INC. | $38.18 | 2019 | |
| Novartis Pharmaceuticals Corporation | $34.76 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.78 | 2025 | Jardiance |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Scpharmaceuticals INC. | $13.23 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Hines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.